Glenmark Pharmaceuticals Limited (Glenmark) has announced impressive financial results for the first quarter of FY 2024-25, marked by a 6.9% increase in consolidated revenue and notable improvements in profit margins. For the quarter ending June 30, 2024, Glenmark’s consolidated revenue was ₹3,244.2 crores, up from ₹3,036.1 crores in the same period last year. EBITDA surged […]
Glenmark Pharmaceuticals Limited, a research-led, global pharmaceutical company, today released its financial results for the fourth quarter ending March 31, 2024, showcasing a solid performance across its diversified markets despite some challenges in North America. Glenmark Pharmaceuticals Financial Highlights and Performance For the fourth quarter of FY 2023-24, Glenmark reported a consolidated revenue of Rs. […]
Glenmark Pharmaceuticals said that it has secured marketing approval for Ryaltris, a fixed-dose combination nasal spray, in 13 countries across the European Union (EU) and the UK. Ryaltris (olopatadine 665 µg and mometasone furoate 25 µg) has approval for the symptomatic treatment of seasonal and perennial allergic rhinitis in adults and children, aged over 12. […]